Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System
Top Cited Papers
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (3), 920-928
- https://doi.org/10.1158/1078-0432.ccr-06-1695
Abstract
Purpose: The CellSearch system (Veridex, Warren, NJ) is designed to enrich and enumerate circulating tumor cells (CTCs) from peripheral blood. Here, we validated the analytic performance of this system for clinical use in patients with metastatic breast cancer. Experimental Design: This prospective multicenter study conducted at three independent laboratories involved samples from 92 patients with metastatic breast cancer. Intra- and inter-assay variability using controls containing defined numbers of cells (average, 50 and 1,000, respectively), cell stability based on varying storage and shipment conditions, recovery precision from samples spiked with 4 to 12 tumor cells, inter-instrument variability, and positivity of samples from metastatic breast cancer patients were tested. Results: Intra- and inter-assay precision for two sites were high: All eight positive controls analyzed in the same run and >95% of the run to run control values (n = 299) were within the specified ranges. Recovery rate of spiked samples averaged between 80% and 82%. CTCs were detected in ∼70% of metastatic breast cancer patients. CTC values of identical samples processed either immediately after blood drawing or after storage for 24, 48, or 72 h at room temperature or at 4°C did not differ significantly. Shipment of samples had no influence on CTC values. When analyzing identical samples in different centers, inter-instrument accordance was high. Conclusions: The CellSearch system enables the reliable detection of CTCs in blood and is suitable for the routine assessment of metastatic breast cancer patients in the clinical laboratory. Blood samples should be shipped at room temperature and CTC counts are stable for at least 72 h.Keywords
This publication has 35 references indexed in Scilit:
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006
- Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patientsBreast Cancer Research and Treatment, 2006
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative ActivityClinical Cancer Research, 2005
- Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometryCytometry Part A, 2005
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- HER-2 gene amplification can be acquired as breast cancer progressesProceedings of the National Academy of Sciences, 2004
- Dissecting the metastatic cascadeNature Reviews Cancer, 2004
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000